Blocking the ALCAM-CD6 axis, either using neutralizing antibody or genetic deletion, has shown alleviating effects for several diseases, including experimental encephalomyelitis, asthma, and even COVID-19 (21–24). The gene discussed is ALCAM; the disease is asthma.